LAS VEGAS, April 18, 2019 /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD), a non-profit, independent society focused on improving CNS drug development, announced today that Sharon Mates, Ph.D., Co- Founder, Chairman, and Chief Executive Officer, of Intra-Cellular Therapies, is the recipient of the ISCDD 2019 Leadership Award and David Daniel, M.D, SVP and CMO at CRF Bracket, and Gary Sachs, M.D., Clinical Vice President at CRF Bracket, are the recipients of the ISCDD 2019 Scientific Leadership Awards at its 17th Annual Meeting.
The ISCDD 2019 Awards were presented by Dr. Raymond Sanchez, the Chairman of the ISCDD Executive Committee, and Dr. Amir Kalali, Executive Secretary of the ISCDD Executive Committee.
Dr. Raymond Sanchez stated, "We honor Drs. Sharon Mates, David Daniel and Gary Sachs with the ISCDD Leadership Awards for their long-term leadership, commitment, and contributions in advancing the delivery of innovative treatments to patients with brain disorders."
Dr Kalali commented, "During the selection process this year, there was a strong consensus that this year's award winners clearly represented what we strive toward as we develop new treatment options for our patients."
Dr. Mates was selected for the award based on her leadership and contributions to basic neuroscience, clinical development, as well as her leadership in founding and developing an integrated biotechnology company, Intra-Cellular Therapies (ITI), with Nobel Laureate Dr. Paul Greengard, Dr. Allen Fienberg, and Moshe Alafi.
Dr. Daniel and Dr. Sachs were selected for the award based on their globally recognized leadership in establishing reliable methodologies to improve the conduct of clinical research and their unwavering commitment and passion to impact the care of patients. Dr. Daniel provides overall scientific, clinical and strategic direction for CRF Bracket's Scientific Services. Dr. Gary Sachs is the Therapeutic Area Leader in bipolar disease and mood disorders at CRF Bracket.
Dr. Mates stated, "I am honored to accept this award from the ISCDD and, with the entire scientific team at Intra-Cellular Therapies, stand committed to continue our mission of advancing innovative approaches to improve the lives of patients and their families."
"I am grateful and humbled by this recognition from the ISCDD. I have enormous esteem for my colleagues at ISCDD who represent the leaders in CNS Drug Development. In many ways this award also acknowledges the leadership at CRF Bracket that fosters scientific objectivity and innovation in support of drug development," commented Dr. Daniel.
"It is an honor to receive this award because ISCDD is the premier organization of our peers in drug development. The entire field benefits from the deep well of trust that is established here and our track record of all working together to bring better solutions to patients. Every inch we advance together is a step to reduce suffering. We are proud to contribute to that progress," stated Dr. Sachs.
Founded in 2002 as a leadership forum for central nervous system drug development, the International Society for CNS Drug Development (ISCDD) is a non-profit, independent society focused on improving CNS drug development, through collaboration amongst stakeholders including academia, industry and government.
For more information, please contact: